Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion HINGHAM, Mass., November 5, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovasc
How this was made
The 30-second read
Why it matters
The filing adds to Microbot's IP portfolio, signaling progress toward broader market entry, but without immediate revenue or regulatory milestones the market impact is expected to be modest.
Market read
A modest, positive corporate update for a micro‑cap med‑tech firm; limited short‑term trading relevance.
What to watch
Potential litigation risk over the new adaptor technology and the need for additional funding to scale commercialization.
Background
Microbot Medical filed an 8‑K announcing a new Canadian patent for an adaptor that integrates guidewires or microcatheters with its robotic system.
Ticker impact
Microbot Medical disclosed that the Canadian Intellectual Property Office granted a new patent for an adaptor used with its LIBERTY® Endovascular Robotic System, increasing its issued patents to 45 worldwide.
slight upside as investors view stronger IP protection, but no significant price move expected
Patent grants are positive news for a medical‑device company, yet they rarely trigger large short‑term price swings without accompanying commercial or regulatory milestones.
Market effects
Strengthens the competitive position of endovascular robotics within the med‑tech sector.
Limited to U.S. and Canadian markets where Microbot operates.
Minimal; primarily relevant to investors tracking niche medical‑device innovators.
Counterpoint
The patent may not translate into commercial revenue if regulatory approvals or adoption lag, limiting upside.
Key entities
- companyMicrobot Medical Inc.
NASDAQ‑listed developer of the LIBERTY® Endovascular Robotic System.
- regulatorCanadian Intellectual Property Office
Agency that granted the new patent.
